- Supported exchanges /
- NASDAQ /
- CLYM.NASDAQ
Climb Bio Inc (CLYM NASDAQ) stock market data APIs
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Climb Bio Inc Financial Data Overview
| 1.98 | |
| 1.91 | |
| - | |
| 2.015 | |
| 1.87 | |
| 1.86-11.55 | |
| 0 | |
| 0 | |
| 0 | |
| -0.1327 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Climb Bio Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Climb Bio Inc Earnings via APIs
- Latest Release 2024-11-13
- EPS/Forecast NaN
Get Climb Bio Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
